We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.03 | 1.34% | 2.27 | 559,241 | 10:59:01 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.27 | 2.35 | 2.27 | 2.20 | 2.20 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | -3.81M | -0.0114 | -1.93 | 7.33M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:56:11 | AT | 26,743 | 2.27 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/4/2024 | 07:00 | UK RNS | Immupharma PLC Grant of Share Options |
| 02/4/2024 | 12:52 | ALNC |  Immupharma jumps amid new IP strategy for P140 technology platform |
| 02/4/2024 | 07:03 | UK RNS | Immupharma PLC New intellectual property strategy initiated |
| 25/3/2024 | 12:20 | ALNC | Incanthera says first order from skincare deal doubles |
| 25/3/2024 | 07:25 | UK RNS | Immupharma PLC Incanthera provides Comm'l Update/Revenue F'casts |
| 19/3/2024 | 07:00 | UK RNS | Immupharma PLC Grant of Share Options |
| 14/3/2024 | 07:00 | UK RNS | Immupharma PLC IMMUPHARMA AT BIO-EUROPE SPRING 2024 |
| 06/3/2024 | 13:05 | ALNC | EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up |
| 06/3/2024 | 07:00 | UK RNS | Immupharma PLC Financial, Business and Portfolio Develop't Update |
| 28/12/2023 | 13:35 | UKREG | Immupharma PLC Holding(s) in Company |
Immupharma (IMM) Share Charts1 Year Immupharma Chart |
|
1 Month Immupharma Chart |
Intraday Immupharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 07/4/2024 | 11:37 | IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES | 38,662 |
| 10/10/2022 | 13:36 | Immupharma | - |
| 30/9/2022 | 08:08 | (IMM) ImmuPharma PLC boss excited by “blockbuster potential” of Lupuzor | 79 |
| 27/7/2022 | 14:08 | IMMUPHARMA - Let's Talk about the Negatives | 389 |
| 02/6/2021 | 12:03 | 'One To Watch' Immupharma | 8 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 09:56:11 | 2.27 | 26,743 | 607.07 | AT |
| 09:56:11 | 2.26 | 26,318 | 594.79 | AT |
| 09:56:11 | 2.25 | 100,000 | 2,250.00 | AT |
| 09:56:11 | 2.24 | 124,514 | 2,789.11 | AT |
| 09:47:24 | 2.21 | 100,000 | 2,205.10 | O |
| Top Posts |
|---|
Posted at 19/4/2024 09:20 by Immupharma Daily Update Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 2.24p.Immupharma currently has 333,403,115 shares in issue. The market capitalisation of Immupharma is £7,468,230. Immupharma has a price to earnings ratio (PE ratio) of -1.96. This morning IMM shares opened at 2.20p |
Posted at 06/3/2024 12:20 by lord loads of lolly nobbygnome - You say IMM looks cheap, is priced to fail and that its holding & warrants in Incanthera could prove a significant asset.So despite your reservations about any imminent deals to provide upfront cash, do you regard IMM as over or under valued at its current level (post-today's uptick)? Notwithstanding McCarthy's pre-disposition to - ahem - exaggerate, I view today's RNS as a major positive. Assuming he doesn't totally go back on his word in a few weeks' time (admittedly a big assumption), surely the major fear that IMM was about to go bust has been dispelled. For now at least. To me, this is now a share to hold & sell closer to (but importantly before!) any trial readout. Your thoughts? |
Posted at 06/3/2024 09:00 by sicilian_kan P.S. They already have two deals, on US rights in Lupuzor with P3 fully funded, and 10% of Incancthera that has a deal with the worlds largest international health and beauty retailer. This is just not factored into the share price. |
Posted at 06/3/2024 08:46 by sicilian_kan Outstanding RNS. Remember IMM is currently priced to go bust, despite holding significant assets and today it being confirmed that there are no current plans to raise equity and that future cash requirements are expected to be non dilutive from up front payments in new commercial deals with unpartnered assets. Active discussions / a bread range of discussions confirmed.Among the assets are: 1. Fully funded P3 trial for Lupuzor, which IMM has double digit tiered royalties on up to 17% and milestone payments, whilst retaining all non-US rights that they hope to partner on this year. The US only deal itself is worth more than the current market cap, let alone the ROW rights that they can sell. 2. They have the worldwide rights for Lupuzor in CIPD that can go straight into a P2/3 and which they hope to partner on. Again, any deal would dwarf the current market cap. Orphan drug status being submitted which again would provide a large boost to the share price even before a deal. 3. The worldwide rights for BioAMB, an anti-infective program that they also hope to partner on. Part 1 of new dose ranging study in animal model complete and no toxisity. Moving to Part 2. Intial partnering discussions have commenced. 4. IMM owns 10.8% (as well as 7.3m warrants) in Incanthera, which concluded a significant commercial skincare deal with part of the AS Watson Group. This is the world's largest international health and beauty retailer owning brands like Superdrug, The Perfume Shop and many others. Significant revenues and profitability are expected to commence for Incanthera in 2024. 5. Overheads reduced by more than 75% since the new business plan came in. All for a market cap of £4.7m. Yes, sub £5m market cap, with no funding needs, for double digit royalties in a fully funded P3 trial, 100% of ROW rights to sell for that trial, 100% of CIDP worldwide rights to sell for the same drug to go into P2/3 trial, 10.8% share of a company expected to generate revenues and profitability this year with a partnership with the world's largest international health and beauty retailer, anti-infective progress and partnership discussions having commenced, and overheads reduced by 75%. It is in my view one of the most undervalued companies on AIM. It should easily have a market cap of £20m in its current position, or around 5p. And that is before any deals are done. |
Posted at 06/3/2024 08:12 by nobbygnome This is a classic McCarthy over optimistic statement.The anti infective is preclinical and Pharma always prefer to see clinical data before they sign on the dotted line. So the chances of getting a significant upfront for this program is absolutely minimal! With regards to the P140 programs well you have to remember it’s soiled goods because it spectacularly failed its first phase III. Also IMM received no upfront payment from Elan even though in theory it’s a phase III ready drug so it’s hard to believe they will get any significant upfront for the second indication. Ironically the best chance to raise money is the holding in Incanthera which is nothing to do with IMM directly because that looks like it could succeed in the short term. So I don’t hold out much hope for significant deals providing upfront cash to keep the company going in the short term. However you have to say the company is priced to fail and any half decent deal could well precipitate a rise in the price! |
Posted at 08/2/2024 11:20 by lord loads of lolly nobby - agreed. Though as I posted on 6th Feb, assuming the trial still proceeds with Avion's full funding, I suspect IMM's share price will rise significantly at some stage within the next two years or so, closer to readout. This is less in McCarthy's hands now than at any time previously.In the unlikely event it met its endpoints, IMM's share price would go stratospheric. Otherwise, it's likely to be RIP IMM, IMHO. |
Posted at 06/2/2024 17:30 by lord loads of lolly Dr Biotech - interesting. I generally agree and am very sorry to hear about your niece.My only thought re: IMM is that many holders (myself included) are probably hanging on (or averaging down) on the basis the share price could well rise as we get closer to the next trial results. I suspect many doubt this latest trial will actually deliver the goods (assuming it even happens). However, there might still be a way of erasing current paper losses by hanging on, then selling into any pre-readout froth. Of course, there's still a danger that IMM runs out of money before then, or that the expected share price rise never materialises! Your thoughts? |
Posted at 28/1/2024 10:45 by lord loads of lolly Luzley - the current share price reflects consensus view on IMM’s prospects of a SUCCESSFUL trial. Not just its stage of development.Also, there’s a possibility IMM will run out of cash shortly, which would mean a fund raise & yet more dilution. Not hard to see why the share price is where it is currently. Though sentiment could change rapidly, either for better or worse. |
Posted at 31/8/2023 09:23 by lord loads of lolly Yup, it smacks of desperation when the RNS keeps trying to make out there'll be positive newsflow going forward. And that this in turn SHOULD lead to an improved share price. Let's just look at the past sharing agreements shall we? And I quote directly from the RNS:"The Sharing Agreement is similar in structure to those undertaken by the Company with Lanstead in February 2016, June 2019, March 2020, December 2021 and August 2022 respectively. The first three of these arrangements have completed their settlement periods. The February 2016 agreement yielded a net gain to ImmuPharma of approximately £0.6 million more than originally subscribed by Lanstead. The June 2019 and March 2020 agreements yielded approximately £0.9 million and £1.0 million less than originally subscribed by Lanstead respectively. The fourth arrangement runs to March 2024 and is currently yielding approximately £1.1 million less than the pro rata amount originally subscribed by Lanstead on cumulative settlements to date. The fifth arrangement runs to August 2024 and is currently yielding approximately £0.3 million less than the pro rata amount originally subscribed by Lanstead on cumulative settlements to date." So that's five agreements in total, one of which yielded a positive result (+ £0.6m approx). Currently the other four - of which two are already complete - have yielded a cumulative LOSS of £3.3m versus the current share price. WHAT A TRIUMPH! Given the above, how many private investors are likely to beat a path to the Winterflood Retail Access Platform so they can subscribe to the Retail Offer? Answers on a postcard please. Clue: the answer may be a nice round figure. At least it can't be negative. Unlike the Sharing Agreement outcomes to date. |
Posted at 04/8/2022 08:42 by mudbath Thanks for providing some balance, supernumerary and 1bond.So much more edifying than the trite "big plunge coming tomorrow morning" and "Tim is a disgrace!" contributions. The IMM share price might indeed weaken further . In this event, I would hope to benefit from taking a decent position. |
Posted at 12/5/2022 21:46 by mudbath The IMM share price moves as if on a snakes and ladders board where the trades(or dice)that should determine its ascent or descent apparently having no influence.Nevertheless, it is a great stock from which to extract a daily margin, as the MMs seem happy to part with the shares in the morning at 5.75p only to seek their return at 6p or above, after lunch. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
